ORIC’s Redwood-1 trial for enozertinib will test drug against osimertinib or afatinibNov 16Regulatory decisionafatinibAstraZenecaUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
HUTCHMED's Orpathys-Tagrisso filings for lung cancer accepted in Europe and JapanNov 2Clinical readoutAstraZenecaCardiff OncologyUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
BMS posts long-term SAR302503 myelofibrosis results; launches Phase III lung cancer trialOct 8Weekly roundup, 4 itemsBristol Myers Squibbiza-brenUpdated
HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancerSep 29Regulatory decisionAstraZenecaHutchmed
HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer dataSep 24PublicationAstraZenecaHutchmed
BlossomHill reports 45% response rate for BH-30643 in EGFR C797S lung cancerSep 15Clinical readoutBH-30643BlossomHill Therapeutics
HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancerAug 17Clinical readoutAstraZenecaHutchmed
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin